Walleye Capital
REGN icon

Walleye Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Walleye Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Sell
500
-11,900
-96% -$9.11M ﹤0.01% 2865
2025
Q4 		$9.57M Buy
12,400
+6,900
+125% +$4.69M 0.03% 688
2025
Q3 		$3.09M Sell
5,500
-5,200
-49% -$2.94M 0.01% 1251
2025
Q2 		$5.62M Buy
10,700
+5,100
+91% +$2.85M 0.02% 809
2025
Q1 		$3.55M Sell
5,600
-8,900
-61% -$6.12M 0.02% 1009
2024
Q4 		$10.3M Buy
14,500
+3,800
+36% +$3.19M 0.03% 612
2024
Q3 		$11.2M Sell
10,700
-4,500
-30% -$5.01M 0.02% 626
2024
Q2 		$16M Sell
15,200
-4,600
-23% -$4.46M 0.03% 475
2024
Q1 		$19.1M Buy
19,800
+10,600
+115% +$10.1M 0.03% 438
2023
Q4 		$8.08M Sell
9,200
-3,500
-28% -$2.88M 0.02% 798
2023
Q3 		$10.5M Buy
12,700
+11,700
+1,170% +$9.2M 0.03% 547
2023
Q2 		$719K Sell
1,000
-900
-47% -$694K ﹤0.01% 2144
2023
Q1 		$1.56M Buy
1,900
+1,600
+533% +$1.21M 0.02% 865
2022
Q4 		$216K Sell
300
-1,100
-79% -$812K ﹤0.01% 1986
2022
Q3 		$964K Buy
+1,400
New +$881K 0.02% 1004
2020
Q2 		– Sell
-400
Closed -$195K – 906
2020
Q1 		$195K Sell
400
-6,500
-94% -$2.68M 0.04% 448
2019
Q4 		$2.59M Sell
6,900
-4,700
-41% -$1.58M 0.17% 147
2019
Q3 		$3.22M Buy
11,600
+10,400
+867% +$3.08M 0.19% 118
2019
Q2 		$376K Sell
1,200
-1,100
-48% -$366K 0.04% 636
2019
Q1 		$944K Buy
+2,300
New +$947K 0.16% 185

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital's REGN Position: Q1 2026 in Review

Walleye Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 89% in Q1 2026, selling an estimated $24.1M and leaving 4,022 shares worth $3.11M. The position accounts for 0.01% of the portfolio, ranked #1124.

Walleye Capital first reported a position in REGN in Q1 2019 and has held it in 19 quarters since. The position peaked at $49.2M in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Walleye Capital held 4,022 shares of Regeneron Pharmaceuticals worth $3.11M as of Q1 2026.
  • Walleye Capital sold 31,478 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $24.1M.
  • Regeneron Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1124 holding.
  • Walleye Capital first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 19 quarters since.
  • Walleye Capital's Regeneron Pharmaceuticals position peaked at $49.2M in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.